Equine IL-1ra/IL-1F3 Biotinylated Antibody

Catalog #: BAF2466 Datasheet

Catalog #	Availability	Size / Price	Qty
BAF2466

All IL-1ra/IL-1F3 Antibodies

Product Details

FAQs

Supplemental Products

Reviews

Summary Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Equine IL-1ra/IL-1F3 Biotinylated Antibody Summary

Species Reactivity

Equine

Specificity

Detects equine IL-1ra in ELISAs and Western blots. In sandwich ELISAs, approximately 20% cross‑reactivity is observed with rmIL-1ra, less than 5% cross‑reactivity with rrIL-1ra, less than 2% cross‑reactivity with rpIL-1ra, and less than 0.4% cross‑reactivity with rhIL-1ra is observed.

Source

Polyclonal Goat IgG

Purification

Antigen Affinity-purified

Immunogen

Recombinant Equine IL‑1ra/IL‑1F3
His26-Gln177
Accession # O18999.1

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Label

Biotin

Applications

Recommended Concentration

Sample

Western Blot

0.1 µg/mL

Recombinant Equine IL‑1ra/IL‑1F3 (Catalog # 2466-RA)

Equine IL-1ra/IL-1F3 Sandwich Immunoassay

Recommended Concentration

Reagent

ELISA Detection (Matched Antibody Pair)

0.1-0.4 µg/mL

Use in combination with:

Capture Reagent: Equine IL‑1ra/IL‑1F3 Antibody (Catalog # AF2466)

Standard: Recombinant Equine IL-1ra/IL-1F3 Protein (Catalog # 2466-RA)

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Preparation and Storage

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: IL-1ra/IL-1F3

Secreted equine IL-1 receptor antagonist (IL-1ra) is a presumably 22 - 25 kDa glycoprotein produced by variety of cell types that antagonizes IL-1 activity (1 - 3). It is a member of the IL-1 family of proteins that includes IL-1 alpha and IL-1 beta. Although there is little amino acid (aa) identity (< 30%) among the three IL-1 family members, all molecules bind to the same receptors, all show a beta -trefoil structure, and all are believed to have evolved from a common ancestral gene (1 - 4). Equine IL-1ra is synthesized as a 177 aa precursor that contains a 25 aa signal sequence plus a 152 aa mature region. There is one intrachain disulfide bond and one potential N-linked glycosylation site (3, 5, 6). Mature equine sIL-1ra is 78%, 78%, 80%, 82%, and 76% aa identical to mature mouse, human, porcine, canine and bovine IL-1ra, respectively. In human, three non-secreted IL-1ra isoforms have also been identified. It is unknown if such an analogous situation exists in equine. Cells known to secrete IL-1ra include fibroblasts, vascular smooth muscle cells, intestinal columnar epithelium, chondrocytes, macrophages, mast cells, neutrophils and hepatocytes.

There are two type I transmembrane glycoprotein receptors for IL-1ra. The first is the bioactive 80 kDa type I IL-1 receptor (IL-1 RI), and the second is the inert (decoy) 65 kDa type II IL-1 receptor. IL-1ra binding to IL-1 RI competitively blocks IL-1 ( alpha or beta ) binding to the same receptor. This results in receptor ligation without activation (1, 7). The type II IL-1 receptor is inert, and any binding of IL-1ra not only fails to block co-existing IL-1 activity, but may actually potentiate it by removing an IL-1 antagonist. Functionally, all activities attributed to IL-1ra are explained by its role as a competitive inhibitor of IL-1 binding to IL-1 RI (1, 2, 8, 9).

References